A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure (COMMANDER HF)
A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Sponsor: Bayer
Listed as NCT01877915, this PHASE3 trial focuses on Coronary Artery Disease and Heart Failure and remains completed. Sponsored by Bayer, it has been updated 19 times since 2013, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
19 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 14 earlier versions
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Sep 2018 — Jun 2019 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2018 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Nov 2017 — Feb 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE3
-
Sep 2017 — Oct 2017 [monthly]
Recruiting PHASE3
-
Jul 2017 — Sep 2017 [monthly]
Recruiting PHASE3
-
Jun 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Mar 2017 — May 2017 [monthly]
Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Janssen Research & Development, LLC
For direct contact, visit the study record on ClinicalTrials.gov .